Friday, May 27 2022

Rockville, Md., May 4, 2022 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced its participation in the following upcoming investor conferences:

Bank of America Securities 2022 Healthcare Conference
Date: Tuesday, May 10, 2022
Location: Hotel Encore, Las Vegas, Nevada
Presentation: Tuesday, May 10, 2022 to 4:00 PM PT

UBS Global Healthcare Conference 2022
Date: Tuesday, May 24, 2022
Location: Lotte New York Palace, New York, NY
Presentation: Tuesday, May 24, 2022 to 10:45 a.m. ET

A webcast of both presentations can be accessed in the Investors section of the REGENXBIO website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of the REGENXBIO website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company focused on improving lives through the healing potential of gene therapy. REGENXBIO’s NAV technology platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform licensees apply the NAV Technology Platform in the development of a wide range of candidates in multiple therapeutic areas.

contacts:

Dana Cormac
Business communication
[email protected]

Investors:
Chris BrinzeyICR Westwicke
339-970-2843
[email protected]

SOURCE REGENXBIO Inc.

Previous

Temple & Webster launch online home improvement website

Next

Corporate Home Buyers Raise Rents, Prices in Newark, Report Says; city ​​greeting action

Check Also